Home > Quotes > ARIA
ARIA

ARIAD Pharmaceuticals, Inc. Stock Quote & Summary Data

$19.57
*  
0.13
  negative  
0.67%
Get ARIA Alerts
*Delayed - data as of May 24, 2013 
Exchange: NASDAQ
Industry: Health Care
Community Rating:
 
 

Symbol List Views

Stock Details

CHARTS

COMPANY NEWS

STOCK ANALYSIS

FUNDAMENTALS

HOLDINGS

Edit Symbol List
Enter up to 25 symbols separated by commas or spaces in the text box below. These symbols will be available during your session for use on applicable pages.


Don't know the stock symbol? Use the symbol lookup tool.

Alphabetize the sort order of my symbols 
Symbol Lookup
Log in or Register
 Save stocks for next time
 | Sponsored

Best Bid /Ask: N/A / N/A
1 Year Target: 28
Today's High/Low:  / 
Share Volume:
50 Day Avg. Daily Volume This is the average share volume for the past 50 trading days, for NASDAQ stocks and 90 trading days for Non-NASDAQ stocks. This field allows you to compare today’s trading to the average daily volume. 3,341,323
Previous Close: $ 19.44
52 Week High /Low: $ 25.40 / $ 15.13
Market cap “Market Capitalization” is a measure of the estimated value of the common equity securities of the company or their equivalent. It does not include securities convertible into the common equity securities. “Market Capitalization” is derived from the last sale price for the displayed class of listed securities and the total number of shares outstanding for both listed and unlisted securities (as applicable). NASDAQ does not use this value to determine compliance with the listing requirements. 3,614,393,985
Annualized dividend N/A
Ex Dividend Date N/A
Dividend Payment Date N/A
Current Yield 0 %
Beta 0.88
NASDAQ Official Open Price NASDAQ Official Opening Price: This process identifies the NASDAQ-specific opening prices for NASDAQ-listed issues. $ 19.43
Date of Open Price This field refers to the date the NASDAQ Official Open Price was disseminated for a given stock. It is possible that the date will not be from the current trading day; this indicates that the stock didn't trade on NASDAQ during the current trading day. The NASDAQ Official Open Price is updated only when the stock is traded on NASDAQ. May 24, 2013
NASDAQ Official Close Price The NASDAQ® Official Closing Price (NOCP) is a process for identifying the NASDAQ market-specific closing price for NASDAQ-listed issues. The NOCP replaces the NASDAQ market-specific closing price that was based solely on the last reported NASDAQ trade. Subject to review by NASDAQ MarketWatch, the NOCP will equal the normalized price of the last trade reported to NASDAQ’s proprietary trade reporting system—Automated Confirmation Transaction ServiceSM (ACTSM—with a last sale eligible sale condition modifier as of 4:00:02 p.m., US Eastern Time. "Normalizing" the NOCP means it will be adjusted to the nearest prevailing inside quote whenever the last sale is reported away from the inside market. Market participants, data distributors and investors will be provided with the NOCP for all NASDAQ Global Select MarketSM, NASDAQ Global MarketSM and NASDAQ Capital MarketSM securities. $ 19.57
Date of Close Price This field refers to the date the NOCP was disseminated for a given stock. It is possible that the date will not be from the prior day; this indicates that the stock didn't trade on NASDAQ on the prior day. The NOCP is updated only when the stock is traded on NASDAQ. May 24, 2013
Community Sentiment

 Intraday Chart

5d | 1m | 6m | 12m | More Charting

ETFs with ARIA as a Top 10 Holding*

Weighting ETF Name (Symbol) 100-Day Price Change (%)
0.93% iShares Morningstar Small Growth Index Fund (JKK) +5.46  (6.03%)
0.49% Vanguard Small-Cap Growth ETF (VBK) +12.05  (13.67%)
0% QuantShares U.S. Market Neutral Momentum Fund ETF (MOM) -0.72  (-2.94%)

We make it easy to follow the leaders. PowerShares QQQ. 100 companies at the top of innovation in one fund.


*Data is provided by Barchart.com. Data reflects weightings calculated at the beginning of each month. Data is subject to change.

**Green highlights the top performing ETF by % change in the past 100 days.

 Company Description (as filed with the SEC)

The following Business Section contains forward-looking statements. Our actual results could differ materially from those anticipated in these forward-looking statements as a result of certain risks, uncertainties and other factors including the risk factors set forth in Part I, Item 1A of this annual report. Unless the content requires otherwise, references to “ARIAD,” “company,” “we,” “our,” and “us,” in this annual report refer to ARIAD Pharmaceuticals, Inc. and our subsidiaries. Overview ARIAD is a global oncology company whose vision is to transform the lives of cancer patients with breakthrough medicines. Our mission is to discover, develop and commercialize small-molecule drugs to treat cancer in patients with the greatest and most urgent unmet medical need – aggressive cancers where current therapies are inadequate.  ... More ...  



News Headlines for ARIA

Daniel Loeb's Top Three Increases of the First Quarter
5/24/2013 7:25:07 PM - GuruFocus
ARIAD to Present at the Deutsche Bank 38th Annual Healthcare Conference
5/23/2013 7:35:00 AM - Business Wire
Ariad's Cancer Drug Iclusig Extends The Gleevec Magic
5/22/2013 1:20:00 PM - Seeking Alpha
Ariad Pharma To Present At UBS Global Conference ; Webcast At 8:30 AM ET
5/20/2013 7:30:00 AM - RTT News
ARIAD Announces Data Presentations and Webcast of Investor Briefing at the 2013 ASCO Annual Meeting
5/15/2013 6:04:00 PM - Business Wire
 

Consensus Recommendation